ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Nasal Polyps
Rhinosinusitis
Allergic Rhinitis
Rhinitis
Chronic Obstructive Pulmonary Disease
Lung Diseases

Asthma trials near Montréal, QC, CAN:

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations ...

Enrolling
Asthma
Drug: Placebo
Drug: Benralizumab

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 83 other locations

compared with placebo in participants with moderate-to-severe asthma.Study details include:* The study duration for each participant will be...

Enrolling
Asthma
Drug: Placebo to AZD4604
Drug: AZD4604

Phase 2

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 24 other locations

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled co...

Enrolling
Asthma
Biological: Tezepelumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 105 other locations

treatment in children 2 to \<6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted i...

Enrolling
Asthma
Wheezing
Drug: Placebo
Drug: Dupilumab

Phase 3

Sanofi
Sanofi

Montreal, Quebec, Canada and 51 other locations

and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma...

Active, not recruiting
Asthma
Drug: BFF MDI 160/9.6 μg BID (320/19.2μg/day)
Drug: BD MDI 160 μg BID (320 μg/day)

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 103 other locations

of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all partici...

Active, not recruiting
Asthma
Biological: GSK3511294 (Depemokimab)
Biological: Mepolizumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Greenfield Park, Canada and 419 other locations

the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma...

Active, not recruiting
Asthma
Drug: BD MDI 320 μg
Drug: Open-label Symbicort TBH 320/9 μg

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 143 other locations

decline in adult patients with uncontrolled moderate to severe asthma.The estimated duration is 4±1 weeks of screening and run-in period, fo...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

Phase 4

Sanofi
Sanofi

Montreal, Quebec, Canada and 218 other locations

Primary Objective-To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smellSecondary Objec...

Active, not recruiting
Asthma
Chronic Rhinosinusitis With Nasal Polyps
Drug: Omalizumab
Drug: Placebo

Phase 4

Sanofi
Sanofi

Montreal, Quebec, Canada and 94 other locations

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).

Active, not recruiting
Nasal Polyps
Drug: Placebo
Biological: Depemokimab (GSK3511294)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Montreal, Canada and 105 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems